SYNAREL

This brand name is authorized in United States. It is also authorized in Australia, Canada, France, Ireland, Israel, Netherlands, Spain, Turkey, UK.

Active ingredients

The drug SYNAREL contains one active pharmaceutical ingredient (API):

1	Nafarelin UNII 8ENZ0QJW4H - NAFARELIN ACETATE
	Nafarelin is a potent agonistic analogue of gonadotrophin releasing hormone (GnRH). Given as a single dose, nafarelin stimulates release of the pituitary gonadotrophins, LH and FSH, with consequent increase of ovarian and testicular steroidogenesis.
	Read more about Nafarelin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SYNAREL Nasal spray, solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01CA02	Nafarelin	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CA Gonadotropin-releasing hormones
Discover more medicines within H01CA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2962X, 5815C
CA	Health Products and Food Branch	02188783
ES	Centro de información online de medicamentos de la AEMPS	60079
FR	Base de données publique des médicaments	63954950
GB	Medicines & Healthcare Products Regulatory Agency	38228
IE	Health Products Regulatory Authority	88190
IL	מִשְׂרַד הַבְּרִיאוּת	4996
NL	Z-Index G-Standaard	14243660
NL	Z-Index G-Standaard, PRK	51675
TR	İlaç ve Tıbbi Cihaz Kurumu	8699543540023
US	FDA, National Drug Code	0025-0166